Stocks Health care RMTI
NASDAQ · Health careRockwell Medical, Inc. (RMTI)
Rockwell Medical, Inc. brought in $69.4M of revenue over the twelve months to June 30, 2026, down 21.1% from a year earlier. It posted a net loss of $5.1M. In fiscal 2025 capital spending exceeded operating cash flow by $1.2M. At June 30, 2026 it held $10.5M in cash against $9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Rockwell Medical, Inc.
- Net worth
- Rockwell Medical, Inc. has a market value (market cap) of $30.4M at the latest share price, and shareholders' equity of $35.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $69.3M (-31.8% year on year), with a net loss of $5.3M. Over the 12 months to June 30, 2026: revenue $69.4M, net loss $5.1M.
- Cash flow
- In fiscal 2025 operations used $659K of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rockwell Medical, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
What Rockwell Medical, Inc. does
Rockwell Medical, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RMTI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $69.3M | -$5.3M | -$0.15 | -$1.2M |
| 2024 | $101.5M | -$480K | -$0.03 | $3.2M |
| 2023 | $83.6M | -$8.4M | -$0.37 | -$9.7M |
| 2022 | $72.8M | -$18.7M | -$1.31 | n/a |
| 2021 | $61.9M | -$32.7M | -$2.65 | n/a |
| 2020 | $62.2M | -$30.9M | -$3.11 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RMTI ranks in Health care
Latest SEC filings
What Rockwell Medical, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $17.8M versus the same quarter last year; diluted EPS -$0.34 versus -$0.05.
- August 13, 2026
- July 20, 2026Other event 8-K
- June 29, 2026
- June 15, 2026
- May 11, 2026Additional proxy material DEFA14A
- May 8, 2026
- May 7, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 8.3% to $17.3M versus the same quarter last year; diluted EPS -$0.04 versus -$0.04.
Insider trades
What the people running Rockwell Medical, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $8.4K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Strobeck MarkPresident and CEO, Director | Soldpre-planned (10b5-1) | 1,000 | $8.4K |
| July 1, 2026 | Strobeck MarkPresident and CEO, Director | Received as pay | 30,000 | - |
| July 1, 2026 | Neri JesseSVP and CFO | Received as pay | 15,000 | - |
| July 1, 2026 | Timmins Megan C.EVP, CLO & Secretary | Received as pay | 15,000 | - |
| July 1, 2026 | Hunter HeatherChief Operating Officer | Received as pay | 15,000 | - |
| July 1, 2026 | Chole TimothySVP and CCO | Received as pay | 15,000 | - |
| July 1, 2026 | Cooper John GDirector | Received as pay | 9,633 | - |
| July 1, 2026 | Radie Robert SDirector | Received as pay | 9,633 | - |
Who owns RMTI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Irrevocable Larson Family Investment Trust13G, passive | 10.7% | December 17, 2024 |
Largest institutional holders
Insiders
10 insiders reported holding 279,744 shares in total, about $2.1M at the last price.
| Holder | Shares |
|---|---|
| Strobeck MarkPresident and CEO, Director | 61,349 |
| Timmins Megan C.EVP, CLO & Secretary | 31,240 |
| Hunter HeatherChief Operating Officer | 28,007 |
| Chole TimothySVP and CCO | 27,285 |
| Neri JesseSVP and CFO | 27,239 |
| Radie Robert SDirector | 23,985 |
| Nissenson AllenDirector | 23,892 |
| Cooper John GDirector | 23,670 |
| Lau JoanDirector | 20,944 |
| Dawson Joseph HDirector | 12,133 |
Questions about RMTI
What does Rockwell Medical, Inc. do?
Rockwell Medical, Inc. is a company in the Health care sector, listed on NASDAQ as RMTI. Its shares trade on NASDAQ under the ticker RMTI.
What is Rockwell Medical, Inc.'s net worth?
Rockwell Medical, Inc. has a market value (market cap) of $30.4M at the latest share price, and shareholders' equity of $35.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rockwell Medical, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $5.1M on revenue of $69.4M.
How much revenue does Rockwell Medical, Inc. make?
Over the twelve months to June 30, 2026 Rockwell Medical, Inc. reported revenue of $69.4M. That is 21.1% less than a year earlier.
When did Rockwell Medical, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 5, 2026.
When is Rockwell Medical, Inc.'s next earnings report?
Rockwell Medical, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
Similar companies
Compare RMTI with
Follow RMTI
Get an email when Rockwell Medical, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rockwell Medical, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.